

Disclosure Purpose: 22-06725

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
National Center for Advancing Translational Sciences	Grant / Contract	Self
<i>Recipient Name:</i> Ohio State University Center for Clinical and Translational Science <i>Grant / Contract Description:</i> UL1TR002733 NCATS grant that helps fund the CCTS at OSU <i>Additional Information:</i> Funded through the CCTS for salary and consultation services.		
<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
National Center for Advancing Translational Sciences	Grant / Contract	Self
<i>Recipient Name:</i> Joseph Bednash <i>Grant / Contract Description:</i> KL2TR002734 <i>Additional Information:</i> Grant support for salary, supplies and consultation through the Ohio State CCTS funded by NCATS CTSA grant UL1TR002733		
<i>Recipient Type:</i> Individual <i>Grant / Contract Purpose:</i> Research		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Neutralization of the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 22-06725

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Neutralization of the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 22-06725

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
The Ohio State University College of Veterinary Medicine	Grant / Contract	Self
<i>Recipient Name:</i> John P. Evans <i>Grant / Contract Description:</i> Glenn Barber Fellowship <i>Additional Information:</i> This grant covers a graduate student's tuition, fees, and stipend for a period of 2 years.		<i>Recipient Type:</i> Individual <i>Grant / Contract Purpose:</i> Research

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
No.
- What is the manuscript title?
Neutralization of SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants
- Are you the corresponding author?
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 22-06725

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
National Institutes of Health	Grant / Contract	Self
<i>Recipient Name:</i> Shan-Lu Liu <i>Grant / Contract Description:</i> Additional support of S.-L.L.'s lab includes NIH grant R01 AI150473. <i>Additional Information:</i>		<i>Recipient Type:</i> Individual <i>Grant / Contract Purpose:</i> Research

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Neutralization of SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 22-06725

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
National Cancer Institute	Grant / Contract	Self
<i>Recipient Name:</i> The Ohio State University <i>Grant / Contract Description:</i> U54CA260582 <i>Additional Information:</i> 15% effort		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
National Institute of Health	Grant / Contract	Self
<i>Recipient Name:</i> The Ohio State University <i>Grant / Contract Description:</i> U54ca260582 <i>Additional Information:</i> 15% effort		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Ohio State University	Employment	Self
<i>Title:</i> Associate Professor of Internal Medicine <i>Additional Information:</i>		<i>Position Description:</i> Associate Professor of Internal Medicine. Interventional Cardiology
Ohio State University	Gift	Self
<i>Description:</i> JB Cardiovascular Research Fund		<i>Additional Information:</i>
Ohio State University	Grant / Contract	Self
<i>Recipient Name:</i> Richard J. Gumina <i>Grant / Contract Description:</i> Robert J. Anthony Fund for Cardiovascular Research <i>Additional Information:</i>		<i>Recipient Type:</i> Individual <i>Grant / Contract Purpose:</i> Research

Intellectual Property

Type	Is Licensed	Interest Held By
Patent - METHODS OF MODULATING T-CELL ACTIVATION USING ES ...	No	Self
<i>Description:</i> METHODS OF MODULATING T-CELL ACTIVATION USING ESTROGEN RECEPTOR BETA (ERbeta) AGONISTS <i>Patent Holder:</i> Current Institution <i>Licensees:</i>	<i>Patent Number:</i> US Provisional Application No: 62/988,251 and PCT/US2021/021903 <i>Patent Status:</i> Pending <i>Filing Jurisdiction:</i> USA <i>Additional Information:</i> Summary: Disclosed herein are methods of modulating immune response in a subject using estrogen receptor beta (ERbeta agonists). The ER-beta agonists can selectively inhibit the activation and/or proliferation of T-cells, reducing circulating T-cell levels in a subject without significantly affecting circulating levels of neutrophils, monocytes, or B-cells.	

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
No.
- What is the manuscript title?
Neutralization of the SARS-CoV-2 Omicron BA.4/5 nd BA.2.12.1 Subvariants
- Are you the corresponding author?
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 22-06725

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
College of Veterinary Medicine, Ohio State University	Gift	Other - I am an employee of the College of Veterinary Medicine at OSU.
<i>Description:</i> A fund provided by an anonymous private donor to the Ohio State University (to Dr. Liu).		<i>Additional Information:</i>
National Cancer Institute	Grant / Contract	Self
<i>Recipient Name:</i> Shan-Lu Liu <i>Grant / Contract Description:</i> U54CA260582 <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
National Institutes of Health	Grant / Contract	Self
<i>Recipient Name:</i> Shan-Lu Liu <i>Grant / Contract Description:</i> R01AI150473 <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
No.
- What is the manuscript title?
Neutralization of the SARS-CoV-2 Deltacron and BA.3 Variants
- Are you the corresponding author?
Yes.
 - Please list the other authors' names here.
Panke Qu, M.S. Julia Faraone, B.S. John P. Evans, M.S. Xue Zou, Ph.D. Yi-Min Zheng, M.D. Claire Carlin Joseph S. Bednash, M.D. Gerard Lozanski, M.D. Rama Mallampalli, M.D. Linda J. Saif, Ph.D. Eugene M. Oltz, Ph.D. Peter Mohler, Ph.D. Richard J. Gumina, M.D., Ph.D.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 22-06725

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
National Cancer Institute	Grant / Contract	Self
<i>Recipient Name:</i> Gerard Lozanski <i>Grant / Contract Description:</i> NIH U54CA260582 <i>Additional Information:</i>		<i>Recipient Type:</i> Individual <i>Grant / Contract Purpose:</i> Research

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Neutralization of SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 22-06725

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Neutralization of SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 22-06725

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Neutralization of the SARS-CoV-2 Deltacron and BA.3 Variants
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 22-06725

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
National Institutes of Health	Grant / Contract	Self
<i>Recipient Name:</i> The Ohio State University <i>Grant / Contract Description:</i> NIH Grant U54CA260582 <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Neutralization of SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 22-06725

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Neutralization of SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 22-06725

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
National Cancer Institute	Grant / Contract	Self
<i>Recipient Name:</i> Linda J Saif <i>Grant / Contract Description:</i> U54CA260582. <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
NIH Office of the Director	Grant / Contract	Self
<i>Recipient Name:</i> Linda J Saif <i>Grant / Contract Description:</i> HD095881 <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
No.
- What is the manuscript title?
Neutralization of SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants"
- Are you the corresponding author?
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 22-06725

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Neutralization of SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 22-06725

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Neutralization of SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

